|Articles|August 1, 2013
TransCelerate Methodology
Craig Wozniak, head Americas region, clinical operations at GlaxoSmithKline, discusses TransCelerate and it's impact on the clinical trials industry and risk-based monitoring.
Advertisement
Craig Wozniak, head Americas region, clinical operations at GlaxoSmithKline, discusses TransCelerate and it's impact on the clinical trials industry and risk-based monitoring
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Patient Centricity: What Rare Disease Research Gets Right
2
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
3
The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness
4
ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files
5